Stockreport

Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]

Monte Rosa Therapeutics, Inc.  (GLUE) 
PDF MRT-6160, a VAV1-directed MGD designed to treat systemic and neurological autoimmune diseases, progressing toward expected IND submission in Q2 2024 and initiation of P [Read more]